45 related articles for article (PubMed ID: 24369221)
21. A panel containing PD-1, IL-2Rα, IL-10, and CA15-3 as a biomarker to discriminate breast cancer from benign breast disease.
Liu C; Sun B; Xu B; Meng X; Li L; Cong Y; Liu J; Wang Q; Xuan L; Song Q; Wu S
Cancer Manag Res; 2018; 10():1749-1761. PubMed ID: 29983594
[TBL] [Abstract][Full Text] [Related]
22. Albumin/globulin ratio is negatively correlated with PD-1 and CD25 mRNA levels in breast cancer patients.
Liu C; Wang W; Meng X; Sun B; Cong Y; Liu J; Wang Q; Liu G; Wu S
Onco Targets Ther; 2018; 11():2131-2139. PubMed ID: 29899663
[TBL] [Abstract][Full Text] [Related]
23. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
Goto N; Tsurumi H; Goto H; Shimomura YI; Kasahara S; Hara T; Yasuda I; Shimizu M; Murakami N; Yoshikawa T; Fukuno K; Takahashi T; Kito Y; Takami T; Moriwaki H
Ann Hematol; 2012 May; 91(5):705-714. PubMed ID: 22183251
[TBL] [Abstract][Full Text] [Related]
24. SIL index, comprising stage, soluble interleukin-2 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large B-cell lymphoma.
Tomita N; Sakai R; Fujisawa S; Fujimaki K; Taguchi J; Hashimoto C; Ogawa K; Yamazaki E; Ishigatsubo Y
Cancer Sci; 2012 Aug; 103(8):1518-23. PubMed ID: 22587388
[TBL] [Abstract][Full Text] [Related]
25. Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens.
Goto N; Tsurumi H; Kasahara S; Kanemura N; Hara T; Yasuda I; Shimizu M; Murakami N; Sawada M; Yamada T; Takemura M; Seishima M; Kito Y; Takami T; Moriwaki H
Eur J Haematol; 2011 Sep; 87(3):217-27. PubMed ID: 21575062
[TBL] [Abstract][Full Text] [Related]
26. Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy.
Ennishi D; Yokoyama M; Terui Y; Asai H; Sakajiri S; Mishima Y; Takahashi S; Komatsu H; Ikeda K; Takeuchi K; Tanimoto M; Hatake K
Ann Oncol; 2009 Mar; 20(3):526-33. PubMed ID: 19074749
[TBL] [Abstract][Full Text] [Related]
27. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
[TBL] [Abstract][Full Text] [Related]
28. Prognostic importance of the soluble form of IL-2 receptorα (sIL-2Rα) and its relationship with surface expression of IL-2Rα (CD25) of lymphoma cells in diffuse large B-cell lymphoma treated with CHOP-like regimen with or without rituximab: a retrospective analysis of 338 cases.
Hashimoto Y; Yokohama A; Saitoh A; Nakahashi H; Toyama K; Mitsui T; Koiso H; Saitoh T; Handa H; Uchiumi H; Jinbo T; Murayama K; Matsumoto M; Sawamura M; Karasawa M; Murakami H; Hirato J; Nojima Y; Kojima M; Tsukamoto N
J Clin Exp Hematop; 2013; 53(3):197-205. PubMed ID: 24369221
[TBL] [Abstract][Full Text] [Related]
29. How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma.
Falduto A; Cimino F; Speciale A; Musolino C; Gangemi S; Saija A; Allegra A
Blood Rev; 2017 Jul; 31(4):235-249. PubMed ID: 28262268
[TBL] [Abstract][Full Text] [Related]
30. Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification.
Westin JR; Fayad LE
Curr Hematol Malig Rep; 2009 Oct; 4(4):218-24. PubMed ID: 20425411
[TBL] [Abstract][Full Text] [Related]
31. A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise.
Lue JK; O'Connor OA
Lancet Haematol; 2020 Nov; 7(11):e838-e850. PubMed ID: 33091357
[TBL] [Abstract][Full Text] [Related]
32. The role of tumor-associated macrophages on serum soluble IL-2R levels in B-cell lymphomas.
Sakai A; Yoshida N
J Clin Exp Hematop; 2014; 54(1):49-57. PubMed ID: 24942946
[TBL] [Abstract][Full Text] [Related]
33. The soluble IL-2 receptor α/CD25 as a modulator of IL-2 function.
Lokau J; Petasch LM; Garbers C
Immunology; 2024 Mar; 171(3):377-387. PubMed ID: 38037265
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
